Pulmonary microinvasive small cell carcinoma with an extensive in‐situ component identified after photodynamic therapy for'squamous cell carcinoma in situ': a case …
M Ota, Y Nakatani, T Nakajima, K Hiroshima… - …, 2021 - search.ebscohost.com
Pulmonary microinvasive small cell carcinoma with an extensive in-situ component
identified after photodynamic therapy for" squamous cell carcinoma in situ": a case report …
identified after photodynamic therapy for" squamous cell carcinoma in situ": a case report …
小细胞肺癌潜在治疗靶点研究进展
施甜甜， 王玉栋 - 肿瘤防治研究, 2019 - zlfzyj.com
摘要小细胞肺癌(SCLC) 约占肺癌的15%, 致死率高. SCLC 的病理, 分子生物学机制和临床预后
特征与非小细胞肺癌(NSCLC) 不尽相同. 大多数SCLC 表达神经内分泌特征(整合了神经和 …
特征与非小细胞肺癌(NSCLC) 不尽相同. 大多数SCLC 表达神经内分泌特征(整合了神经和 …
Pulmonary Large-Cell Neuroendocrine Carcinoma: Therapeutic Challenges and Opportunities
G Ioannidis - Forum of Clinical Oncology, 2020 - sciendo.com
Pulmonary large cell neuroendocrine carcinoma (P-LCNEC) is a rare, poorly differentiated,
non-small cell malignancy within the spectrum of neuroendocrine tumors (NETs) of the lung …
non-small cell malignancy within the spectrum of neuroendocrine tumors (NETs) of the lung …
[PDF][PDF] Pulmonale neuroendokrine Tumoren in der neuen WHO-Klassifikation 2015
PA Schnabel, K Junker - Pathologe, 2015 - researchgate.net
Relevant ist eine kleinzellige Morphologie, wobei kleinzellig durch einen Zelldurchmesser
von bis 3 ruhenden Lymphozyten definiert ist [40, 41]. Im Schnellschnitt sowohl an …
von bis 3 ruhenden Lymphozyten definiert ist [40, 41]. Im Schnellschnitt sowohl an …
Lung Tumors in Experimental Models
H Popper - Pathology of Lung Disease: Morphology–Pathogenesis …, 2021 - Springer
Mice, rats, and hamsters have been used as models for human lung cancer for several
decades. In the past, mainly inhalation of tobacco smoke and other carcinogenic substances …
decades. In the past, mainly inhalation of tobacco smoke and other carcinogenic substances …
[PDF][PDF] Clinical Protocol CA001030
EUS Non-IND - classic.clinicaltrials.gov
This document is the confidential and proprietary information of Bristol-Myers Squibb
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it …
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it …
Relationship between neuroendocrine and immune gene expression in small cell lung cancer
L Cai, H Liu, F Huang, J Fujimoto, L Girard, J Chen… - bioRxiv, 2020 - biorxiv.org
Small cell lung cancer (SCLC) is classified as a high-grade neuroendocrine (NE) tumor, but
a subset of SCLC has been termed “variant” due to the loss of NE characteristics. In this …
a subset of SCLC has been termed “variant” due to the loss of NE characteristics. In this …
P53 Gene Mutation Identified by Next Generation Sequencing in Poorly Differentiated Neuroendocrine Carcinoma of the Nasal Cavity
JK Wasserman, D AlGhamdi, JR de Almeida… - Head and Neck …, 2019 - Springer
Neuroendocrine carcinomas (NECs) are epithelial neoplasms showing morphologic,
immunophenotypic or ultrastructural evidence of neuroendocrine differentiation. The 2017 …
immunophenotypic or ultrastructural evidence of neuroendocrine differentiation. The 2017 …
[图书][B] Identification and clinical significance of two divergent regulators in thoracic malignancy: miR-18a and RUNX1T1
T He - 2021 - search.proquest.com
Malignant pleural mesothelioma (MPM) and small cell lung cancer (SCLC) are two major
types of thoracic tumors. Despite distinct features in histology and tumor biology, both SCLC …
types of thoracic tumors. Despite distinct features in histology and tumor biology, both SCLC …
RB1 Loss Accelerates acquired Therapeutic Resistance in EGFR Mutant Lung Adenocarcinoma via Lineage Plasticity
L Zhang - 2021 - search.proquest.com
Lung cancer is the leading cause of cancer death worldwide. Treatment of a subset of non-
small-cell-lung cancer (NSCLC) patients harboring activating EGFR mutations was …
small-cell-lung cancer (NSCLC) patients harboring activating EGFR mutations was …